Indication

As monotherapy for the first‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2375
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
13 September 2021
SMC meeting date:
TBC
Patient group submission deadline:
05 July 2021